.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Gastrointestinal (GI) cancers impose a significant health burden globally, particularly affecting the population in India. Consequently, understanding the Galectin-3 GI cancer biomarker remains vital for improving diagnosis and patient outcomes. The LGALS3 gene encodes this multifunctional protein, which regulates cell adhesion and immune responses. Moreover, recent bioinformatic mapping reveals distinct expression patterns that influence tumor progression.
Specifically, the study indicates that LGALS3 shows significant upregulation in cholangiocarcinoma, esophageal adenocarcinoma, and liver hepatocellular carcinoma. Conversely, researchers observed downregulation in colon and rectal adenocarcinomas. These findings are important because high Galectin-3 levels often predict poorer survival rates, especially in liver and pancreatic cancers. In addition, the protein fosters an immunosuppressive tumor microenvironment. Therefore, clinicians can utilize this information to identify high-risk patients more accurately.
Protein-protein interaction analysis identifies MAPK3 and PTEN as key partners for Galectin-3. Furthermore, gene enrichment data highlights its involvement in T-cell activation and motility regulation. Thus, targeting this protein might enhance the efficacy of current immunotherapies by preventing tumor immune escape. In conclusion, Galectin-3 serves as both a diagnostic tool and a promising therapeutic target for advanced GI malignancies.
Galectin-3 serves as a significant prognostic indicator. High expression levels in liver and pancreatic cancers correlate with advanced disease stages and lower survival rates.
This protein contributes to an immunosuppressive microenvironment. It regulates T-cell activation and allows tumor cells to evade the body's natural defenses more effectively.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or a professional recommendation. Refer to the latest local and national guidelines for clinical practice.
References
Chiriva-Internati M et al. Galectin 3 expression in gastrointestinal tumors identified through comprehensive bioinformatic mapping. Discov Oncol. 2026 Jun 10. doi: 10.1007/s12672-026-04931-3. PMID: 42268362.
Song L, et al. Galectin-3 in cancer: Fondness and functions. J Hematol Oncol. 2014;7:77. doi: 10.1186/s13045-014-0077-0.
Scafetta G, et al. Galectin-3 and cancer immunotherapy: a glycobiological rationale to overcome tumor immune escape. J Exp Clin Cancer Res. 2024;43:41. doi: 10.1186/s13046-024-02968-2.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
A comprehensive bioinformatic mapping study has identified Galectin-3 (LGALS3) as a critical prognostic biomarker across seven gastrointestinal cancers. Elevated expression correlates with poor survival and an immunosuppressive environment, suggesting its potential as a targeted therapeutic option.
3 months ago
Dendritic cells bridge innate and adaptive immunity in myocardial infarction. This review explores their pathological roles, circulating dynamics, novel tolerogenic interventions, and how standard cardiovascular medications modulate dendritic cells to improve post-infarction myocardial repair and patient outcomes.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
Atherosclerosis involves extensive glycometabolic reprogramming across immune and vascular cells. This review examines how glycolysis, the pentose phosphate pathway, and lactate-driven epigenetic shifts fuel plaque vulnerability, while highlighting novel therapeutic targets like PFKFB3 and LDHA.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
